ClinicalTrials.gg
Enrolling by invitationNCT06851767Updated Nov 19, 2026

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

A Phase 1/2 interventional study of Base-edited hematopoietic stem and progenitor cells and Busulfan in X-linked Severe Combined Immunodeficiency, X-SCID and XSCID, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Enrolling by invitation at 1 site in United States. Open to male participants aged 3 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 19, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
3 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.

Planned enrollment
4th of 11
18 · median 12
Started
2025
the only one that year
Phase 1/2
8 of 20
3 open now
Registered
20th of 20
by date
Lead sponsor
8 of 20
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 8 in phase 1/2, and was the 20th registered.

X-Linked Combined Immunodeficiency Diseases

28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.

Browse X-Linked Combined Immunodeficiency Diseases studies →

Open to participants now

5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 3 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

Background:

X-linked severe combined immunodeficiency (XSCID) is a rare inherited disorder that affects the immune system. It is caused by a change in the IL2RG gene. Researchers are investigating a new type of gene therapy for people with XSCID. This technique, called base-edited stem cell transplants, involves collecting a person s own stem cells, editing the genes to repair IL2RG gene, and returning the edited cells to the person.

Objective:

To test base-edited stem cell transplants in people with XSCID.

Eligibility:

People aged 3 years and older with XSCID.

Design:

Participants will be screened. They will have a physical exam. They may give blood, urine, and stool samples. They may have tests of their heart and lung function. They may have fluid and cells drawn from their bone marrow.

Participants will undergo apheresis. Blood will be taken from the body through a needle inserted into 1 arm. The blood will pass through a machine that separates out the stem cells. The remaining blood will be returned to the body through a different needle. The collected stem cells will undergo gene editing.

Participants will be admitted to the hospital before treatment. They will receive a central line: A flexible tube will be inserted into a large vein. This tube will be used to administer drugs and draw blood during their stay. Before receiving the gene edited cells, participants will receive a reduced dose of busulfan, a drug that makes room in the bone marrow for the treated cells. The busulfan dose may be further adjusted for participants with significant organ damage. Alemtuzumab (Campath) may also be given to some participants to address certain immune problems involving donor T cells from a previous transplant.

The base-edited stem cells will be infused through the central line. Participants will remain in the hospital for at least 3 weeks while they recover.

Follow-up visits will continue for 15 years.

...

Read the detailed description

Study Description:

This is a phase 1/2, non-randomized study of a single infusion of autologous hematopoietic stem/progenitor cells base-edited to repair interleukin 2 receptor gamma (IL2RG) mutations (BE-HSPC IL2RG) in 18 participants with X-linked severe combined immunodeficiency (X-SCID).

Primary Objective:

Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID.

Secondary Objectives:

Evaluate efficacy of treatment with BE-HSPC IL2RG in participants with X-SCID.

Exploratory Objectives:

  1. Evaluate off-target (OT) editing activity.
  2. Compare outcomes of immune reconstitution with lentivector (LV) gene therapy.

Primary Endpoint:

Safety of treatment with BE-HSPC IL2RG, by quantifying frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.

Secondary Endpoints (24 months post-study agent infusion):

  1. Percentage of participants with >=5% mutation-repaired myeloid cells.
  2. Editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
  3. Immune reconstitution:

    1. T, B, and NK cell number improvement from baseline.
    2. Emergence of naive T cells and CD31+ recent thymic emigrants.
    3. B-cell function: immunoglobulin (Ig) production.
    4. Specific responses to vaccines.
  4. Clinical efficacy: improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
  5. Frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.

Exploratory Endpoints:

  1. Evaluate for frequency of off-targets (OTs) by high-throughput sequencing (HTS) of the target mutation at 2 years post-infusion.
  2. Compare rates of immune reconstitution with LV-X-SCID gene therapy.
03

Conditions studied

  • X-linked Severe Combined Immunodeficiency
  • X-SCID
  • XSCID

Keywords

  • base editing
  • Gene Therapy
04

Who can participate

Ages eligible
3 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Aged >= 3 years and weigh >=10 kg
  • Patients with X-SCID
  • If previously transplanted, must be >=18 months post-
  • Expected survival of at least 120 days.
  • Ability to undergo apheresis for stem cell collection.
  • Patients with proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA. At this time, only patients with an IL2RG p.Q144X, IL2RG p.R289X, IL2RG p.Q235X and IL2RG p.R226H mutations can be treated.
  • Participants of must agree to consistently use highly effective throughout study participation and for at least 2 years post-treatment.

Acceptable forms of contraception are:

--For males: Condoms or other contraception with partner.

  • Documented to be negative for infection by PCR
  • The patient must be judged by the primary evaluating physician to have a suitable family and social situation consistent with ability to comply with protocol procedures and the long-term follow-up requirements.
  • Medical lab data (historical) of severe B cell dysfunction (low or absent IgG levels, failed immune response to vaccines);

OR

demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels).

-Must be willing to have blood and tissue samples stored IN ADDITION, patients must satisfy the following Laboratory Criteria AND Clinical Criteria

Laboratory Criteria: (>=1 must be present)

  • CD4+ lymphocytes: absolute number \<= 50% of the lower limit of normal (LLN)
  • CD4+5RA+ lymphocytes: absolute number \<= 50% of the LLN OR T-cell receptor excision circles (TRECs) \<= 5% of normal for age.
  • Memory B Cells: absolute number \<= 50% of LLN
  • Serum IgM\<normal for age
  • NK cells: absolute number \<= 50% of LLN
  • Lymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is \<= 25% compared with a normal control.
  • Molecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in >=6 of the 24 V(Beta) T-cell receptor families.

Clinical Criteria: (>=1 must be present)

I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see VII and VIII below):

Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criterion.

Infections are defined as an objective sign of infection

  • (fever >=38.3 degrees Celsius (101 degrees Fahrenheit) or
  • neutrophilia or
  • pain/redness/swelling or
  • radiologic/ultrasound imaging evidence or
  • typical lesion or histology or
  • new severe diarrhea or
  • cough with sputum production.

In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician s intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)

  1. Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics >=14 days

    OR

  2. Hospitalization of any duration for infection

    OR

  3. Isolation of a bacteria, fungus, or virus from , skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection

II. Chronic pulmonary disease as defined by:

  1. Bronchiectasis by x-ray computerized tomography

    OR

  2. Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age

    OR

  3. Pulse oximetry \<=94% in room air (if patient is too young to comply with performance of PFTs).

III. Gastrointestinal enteropathy:

  1. Diarrhea-watery stools >=3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion I. above)

    OR

  2. Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)

    OR

  3. Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level).

IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.

V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes at more than one anatomic site and not due to infection, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.

VI. Failure to grow in height: \<=3rd percentile for age

VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of >=10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are >=3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)

VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)

IX. Hypogammaglobulinemia: requires regular IgG supplementation

Criteria for eligibility for Campath:

Evidence of organ disease attributable to T cell dysregulation (e.g., elevated transaminases)

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Available HLA-matched sibling donors.
  • Known to busulfan or any component of the product.
  • for administration of busulfan.
  • Childhood (occurring before 18 years of age) in the participant or a first degree relative, or previously diagnosed known genotype of the participant conferring a predisposition to cancer unless approved by the Hematology consult team (no DNA or other testing for cancer predisposition genes will be performed as part of the screen for this protocol).
  • Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the participant, or would preclude the patient from successful study completion.
  • Unwilling to submit their information as part of the alemtuzumab (Campath(R)) Distribution Program application or the Distribution Program committee has determined the participant is not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Single Arm Study

    Biological: Base-edited hematopoietic stem and progenitor cells · Drug: Busulfan · Drug: Palifermin · Drug: Filgrastim · Drug: Plerixafor · Drug: Campath

Interventions

  • BiologicalBase-edited hematopoietic stem and progenitor cells

    Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose \>5(SqrRoot) 10\^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy.

  • Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice.

  • DrugFibroblast Growth Factor 7Studies of Fibroblast Growth Factor 7Fibroblast Growth Factor 7 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).

  • Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.

  • Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.

  • DrugAlemtuzumabStudies of AlemtuzumabAlemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Immunomodulating Agent: May be administered subcutaneously Days -21 through Day -19 in patients who demonstrate evidence of donor T cell dysregulation

06

What researchers measure

Primary outcomes

  1. Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.

    Evaluate the safety of treatment with BE-HSPC IL2RG in participants with X-SCID.

    Time frame: 12 months

Secondary outcomes

  1. Evaluate percentage of participants with >= 5% mutation-repaired alleles in PBMCs.

    Measure efficacy of treatment by assessing efficiency of base editor at repair of mutations.

    Time frame: 24 months

  2. Evaluate editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).

    Measure efficacy of treatment by assessing molecular evidence for mutation repair.

    Time frame: 24 months

  3. Evaluate Immune reconstitution: a. T, B, and NK cell number improvement from baseline. b. Emergence of naive T cells and CD31+ recent thymic emigrants.c. B-cell function: immunoglobulin (Ig) production. d. Specific responses to vacci...

    Measure efficacy of treatment by assessing immune reconstitution as indicated by 1) increase in immune cell numbers; 2) restoration of thymic function with production of na(SqrRoot) ve T cells and CD31+ T cells; 3) Evaluate restoration of B-cell function.

    Time frame: 24 months

  4. Evaluate clinical efficacy by improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.

    Measure efficacy of treatment by assessing comparison of clinical status before and after treatment as indicator of response to improved immune function.

    Time frame: 24 months

  5. Evaluate frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.

    Measure efficacy of treatment by assessing intervention-related AE rate.

    Time frame: 24 months

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2034, 115 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Feb 28, 2025
StartActual
May 9, 2025
Primary completionEst.
Dec 31, 2034
CompletionEst.
Dec 31, 2034
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Added Drug: Plerixafor·Drug: Campath; removed Genetic: Plerixafor
Nov 19, 2026
Show all 2 updates
  1. Nov 19, 2026
    Interventions Added Drug: Plerixafor·Drug: Campath; removed Genetic: Plerixafor
    + 3 other changes: index terms, verification date and description
  2. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06851767
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
May 9, 2025
Primary completion
Dec 31, 2034 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Nov 19, 2026

Study contacts

Suk S De Ravin, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Fibroblast Growth Factor 7 · Filgrastim · Plerixafor · Alemtuzumab

Start the discussion